Inventor · disambiguated record
Laurent Poirot
Also filed as: POIROT LAURENT
36 granted patents·28 pending applications·190 citations·filing 2013–2025
97Inventor score
Files withCELLECTIS55CELLECTIS SA5ALLOGENE THERAPEUTICS INC3CENTRO DE INVESTIG BIOMEDICA EN RED CIBER1
Top patents by PatentIndex Score
64 records- 0198US10584352B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2018·Granted Mar 10, 2020·21 cites·20 claims
- 0298US9855297B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2016·Granted Jan 2, 2018·50 cites·17 claims
- 0397US10870864B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Dec 22, 2020·4 cites·18 claims
- 0497US9890393B2Methods for engineering T cells for immunotherapy by using RNA-guided CAS nuclease systemCELLECTIS·Filed 2014·Granted Feb 13, 2018·38 cites·3 claims
- 0595US10286007B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2017·Granted May 14, 2019·12 cites·18 claims
- 0694US11274316B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2021·Granted Mar 15, 2022·2 cites·5 claims
- 0793US10196608B2Method for in situ inhibition of regulatory T cellsCELLECTIS·Filed 2015·Granted Feb 5, 2019·8 cites·16 claims
- 0892US10836998B2Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2015·Granted Nov 17, 2020·5 cites·26 claims
- 0991US10363270B2Methods for engineering allogeneic and immunosuppressive resistant T cell immunotherapyCELLECTIS·Filed 2017·Granted Jul 30, 2019·6 cites·7 claims
- 1090US10426795B2Use of preTalpha or functional variant thereof for expanding TCRalpha deficient T cellsCELLECTIS·Filed 2013·Granted Oct 1, 2019·8 cites·17 claims
- 1189US11186824B2Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patientsCELLECTIS·Filed 2016·Granted Nov 30, 2021·4 cites·22 claims
- 1289US10239948B2Method of engineering multi-input signal sensitive T cell for immunotherapyCELLECTIS·Filed 2014·Granted Mar 26, 2019·16 cites·9 claims
- 1389US2024309397A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2023·Application pending·0 cites
- 1487US11304975B2Methods for engineering allogeneic and highly active t cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 19, 2022·4 cites·6 claims
- 1586US12252699B2Method for generating t-cells compatible for allogenic transplantationCELLECTIS·Filed 2023·Granted Mar 18, 2025·0 cites·12 claims
- 1686US11891614B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2020·Granted Feb 6, 2024·1 cites·16 claims
- 1786US10517896B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Dec 31, 2019·2 cites·19 claims
- 1885US10472613B2Method for modulating car-induced immune cells activityCELLECTIS·Filed 2015·Granted Nov 12, 2019·6 cites·29 claims
- 1984US11072644B2Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2015·Granted Jul 27, 2021·2 cites·21 claims
- 2082US2022177914A1Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cellsCELLECTIS·Filed 2022·Application pending·0 cites
- 2180US12391933B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2023·Granted Aug 19, 2025·0 cites·15 claims
- 2279US11414674B2Use of pre T alpha or functional variant thereof for expanding TCR alpha deficient T cellsCELLECTIS·Filed 2019·Granted Aug 16, 2022·0 cites·10 claims
- 2378US2024360196A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2478US2023357719A1Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2023·Application pending·0 cites
- 2577US11311575B2Methods for engineering highly active T cell for immunotherapyCELLECTIS·Filed 2014·Granted Apr 26, 2022·1 cites·15 claims
- 2675US11959091B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Apr 16, 2024·0 cites·21 claims
- 2775US2025277231A1Method for generating t-cells compatible for allogenic transplantationCELLECTIS·Filed 2025·Application pending·0 cites
- 2872US11603539B2Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapyCELLECTIS·Filed 2013·Granted Mar 14, 2023·0 cites·9 claims
- 2972US11365430B2Methods for engineering T cells for immunotherapy by using RNA-guided Cas nuclease systemCELLECTIS·Filed 2020·Granted Jun 21, 2022·0 cites·20 claims
- 3072US2025034641A1Cellular immunotherapy for repetitive administrationCELLECTIS·Filed 2024·Application pending·0 cites
- 3171US11820996B2Method for generating T-cells compatible for allogenic transplantationCELLECTIS·Filed 2018·Granted Nov 21, 2023·0 cites·14 claims
- 3271US11692169B2Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cellsCELLECTIS·Filed 2020·Granted Jul 4, 2023·0 cites·18 claims
- 3370US2023201260A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3470US2018360883A1Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapyCELLECTIS·Filed 2018·Application pending·0 cites
- 3567US2023050345A1Methods for engineering allogeneic and highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 3667US2022033462A1Inhibitory chimeric antigen receptorsALLOGENE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3766US2025281613A1Enhancing safety of t-cell-mediated immunotherapyCELLECTIS SA·Filed 2023·Application pending·0 cites
- 3863US2025057952A1Enhancing efficacy of t-cell-mediated immunotherapy by modulating cancer-associated fibroblasts in solid tumorsCELLECTIS SA·Filed 2022·Application pending·0 cites
- 3962US12171820B2Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironmentCELLECTIS·Filed 2020·Granted Dec 24, 2024·0 cites·19 claims
- 4060US12209125B2Targeted gene integration of NK inhibitors genes for improved immune cells therapyCELLECTIS·Filed 2018·Granted Jan 28, 2025·0 cites·20 claims
- 4160US2024197880A1New anti-muc1 cars and gene edited immune cells for solid tumors cancer immunotherapyCELLECTIS SA·Filed 2022·Application pending·0 cites
- 4260US2023056268A1Methods for engineering highly active t cell for immunotheraphyCELLECTIS·Filed 2022·Application pending·0 cites
- 4359US11873511B2Targeted gene insertion for improved immune cells therapyCELLECTIS·Filed 2017·Granted Jan 16, 2024·0 cites·19 claims
- 4458US12144825B2Cellular immunotherapy for repetitive administrationCELLECTIS·Filed 2018·Granted Nov 19, 2024·0 cites·20 claims
- 4557US2023279350A1Dual car-t cellsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 4656US12221478B2Targeted gene integration of CRS inhibitor genes for improved immune cells therapyCELLECTIS·Filed 2018·Granted Feb 11, 2025·0 cites·7 claims
- 4756US2023248825A1T-cells expressing immune cell engagers in allogenic settingsCELLECTIS SA·Filed 2021·Application pending·0 cites
- 4854US2025361301A1Method for improving production of car t cellsCELLECTIS·Filed 2025·Application pending·0 cites
- 4953US10765728B2Method for generating immune cells resistant to arginine and/or tryptophan depleted microenvironmentCELLECTIS·Filed 2015·Granted Sep 8, 2020·0 cites·4 claims
- 5051US11903968B2Engineered immune cells resistant to tumor microenvironmentCELLECTIS·Filed 2018·Granted Feb 20, 2024·0 cites·9 claims
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Laurent Poirot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →